🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the effort against superbug strains of the bacteria, according to researchers.

A Global Health Concern

Cases of gonorrhoea are on the rise worldwide, with data suggesting over 82 million infections annually. Particularly high rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an significant and necessary advancement in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices at this time.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Gain Authorization

Zoliflodacin, also known as a brand name, was cleared by the American regulatory agency in December for combating gonorrhoea. This infection can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GSK, also received approval in the same week. This drug, which is employed against UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.

“This milestone signifies a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been staying ahead of medical innovation.”

Research Study Outcomes and Worldwide Availability

Based on results detailed in a prominent scientific publication, zoliflodacin eradicated over nine in ten of uncomplicated infections. This puts it on an comparable level with the current standard treatment, which uses two antibiotics. The research involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of developing nations.

Medical professionals treating patients have expressed positive views. Having a single-dose, oral treatment like this is seen as a "critical tool" for gonorrhoea control. This is viewed as essential to alleviate the strain of the infection for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.